ASL Roma 3 - Presidio Ospedaliero G.B. Grassi
- Address
- Via Giancarlo Passeroni 28, 00122 Ostia Lido (Roma), Italy
ASL Roma 3 - Presidio Ospedaliero G.B. Grassi
ASL Roma 3 - Presidio Ospedaliero G.B. Grassi is a clinical research center specializing in advanced nephrology and kidney disease management. The center demonstrates expertise in conducting complex trials addressing critical renal conditions, with particular emphasis on innovative therapeutic approaches for patients with chronic kidney disease and related complications.
- End-stage kidney disease (ESKD) and cardiovascular outcomes in dialysis patients
- IgA nephropathy (IgAN) with targeted therapy based on kidney biopsy findings
- Novel anti-inflammatory and nephroprotective treatment strategies
The center's research portfolio includes pioneering work in atherosclerotic cardiovascular disease prevention among patients undergoing maintenance dialysis, evaluating innovative biologics such as clazakizumab for reduction of inflammatory markers like high-sensitivity C-reactive protein (hs-CRP). Additionally, the facility is at the forefront of personalized medicine approaches in idiopathic IgA nephropathy, investigating optimal timing and combinations of corticosteroid therapy, renin-angiotensin system blockers (RASBs), and SGLT2 inhibitors to reduce proteinuria while minimizing treatment-related adverse effects in patients with varying degrees of renal pathology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1CSL Behring LLC1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ASL Roma 3 - Presidio Ospedaliero G.B. Grassi
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clazakizumab | 1 | Unknown | 2023-07-17 | 2023-07-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.